The American Transaction Processors Coalition (ATPC) formally launched today with a panel discussion in front of 400 industry employees, chamber of commerce executives, university leadership and elected officials from Congress, the Georgia General Assembly and local governments across metro Atlanta.
More than 40,000 employees work directly for 70-plus Georgia-based transaction processing companies within an area known as Transaction Alley. These companies generated more than $30 billion last year, far exceeding other well-known Georgia industries like life sciences at $17 billion or film at $3 billion. Transaction Alley revenues equal that of the entire U.S. movie industry, and is dominated by Atlanta, just as Los Angeles dominates films.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/7081851-american-transaction-processors-coalition-launches-georgia-town-hall
The Dan David Prize award ceremony took place yesterday at Tel Aviv University, in the presence of Prof. Joseph Klafter, President of Tel Aviv University and Chairman of the Dan David Prize Board, Prof. Ruth Arnon, President of the Israel Academy of Sciences, members of the David family, the 2013 Dan David Prize laureates, foreign ambassadors, and prominent academic and business figures from Israel and abroad.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61910-dan-david-prizes-awarded
Aurora Flight Sciences announced today that the Defense Advanced Research Projects Agency (DARPA) has awarded the company the prime contract for Phase 2 of the Agency’s Vertical Takeoff and Landing Experimental Plane (VTOL X-Plane) program.
VTOL X-Plane seeks to develop a technology demonstrator that could:
• Achieve a top sustained flight speed of 300 kt-400 kt
• Raise aircraft hover efficiency from 60 percent to at least 75 percent
• Present a more favorable cruise lift-to-drag ratio of at least 10, up from 5-6
• Carry a useful load of at least 40 percent of the vehicle’s projected gross weight of 10,000-12,000 pounds
The Aurora team’s design for its unmanned aircraft, named LightningStrike, seeks to provide an approximately 50-percent increase in speed over existing VTOL aircraft designed for comparable mission applications.
To view the multimedia release go to:
http://www.multivu.com/players/English/7617851-aurora-flight-sciences-vtol-xplane-darpa/
Phenogen Sciences, Inc. [www.phenogensciences.com] today announced the immediate availability of BREVAGen™, a predictive risk test for the millions of women at above average risk of developing estrogen-receptor positive breast cancer. This first-in-class, scientifically-validated risk assessment test examines a woman’s clinical risk factors, such as her lifetime exposure to estrogen, combined with scientifically validated genetic markers to determine each patient’s personalized five-year and lifetime risk of developing breast cancer.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58399-phenogen-sciences-brevagen-breast-cancer-risk-assessment-test-availability
There’s a lot more to Hollywood magic than smoke and mirrors – popular movie and TV shows about zombies, superheroes, spaceships and true crime only come to life because of science, technology, engineering and math (STEM).
That’s why Texas Instruments (TI) is launching “STEM Behind Hollywood,” an exciting new education program developed with assistance from The Science & Entertainment Exchange, a program of the National Academy of Sciences, as well as actress, neuroscientist and STEM education advocate Mayim Bialik.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54048-texas-instruments-stem-behind-hollywood-program-with-mayim-bialik
Grammy and Emmy award winner, and Tony award nominee, the multi-talented musician, singer and actor Harry Connick, Jr. and his wife of 24 years and former model, Jill Connick, recently marked the fifth anniversary of Jill’s recovery from breast cancer. As Jill credits timely screening and early detection for being a cancer survivor today, she is joining Harry to share their experience and to raise awareness of another cancer for which timely screening is critical: colon cancer.* Their efforts will support The New 50, a public education campaign sponsored by Exact Sciences, that debuts today during Colorectal Cancer Awareness Month. The initiative aims to encourage people 50 and older to talk with their healthcare provider about screening, including the modern, noninvasive options that can fit into any schedule of this busy, on-the-go “new 50” generation.
To view the multimedia release go to:
https://www.multivu.com/players/English/8280451-harry-and-jill-connick-colon-cancer-screening-the-new-50/
GB Sciences, Inc. (OTCQB: GBLX) announces the success of its first annual, “Innovation in Medical Cannabis Therapies” (IMCT) Symposium, held on Friday, November 9th at the “Keep Memory Alive” Event Center at the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada. Throughout the day’s program, there was an emerging sense of heightened responsibility on the part of the cannabis industry to better address medical cannabis patients' needs through research and development of medical cannabis products that are better standardized, more easily-dosed, and made more widely-available to cannabis patients at a fair price.
To view the multimedia release go to:
https://www.multivu.com/players/English/8308958-gb-sciences-2018-medical-cannabis-therapies-symposium/
Phenogen Sciences, Inc. today announced the availability of BREVAGenplus, an easy-to-use predictive risk test for the millions of women at risk of developing sporadic, or non-hereditary, breast cancer. The test is an enhancement of the company’s first generation product, BREVAGen®. BREVAGenplus assesses both clinical risk factors and genetic markers known to be associated with sporadic, or non-hereditary, breast cancer to determine a woman’s five-year and lifetime risk of developing the disease. The test is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans for Caucasian, Hispanic and African-American women, age 35 years or above, who have not had breast cancer, lobular carcinoma in situ (LCIS) or ductal carcinoma in situ (DCIS), and have one or more risk factors for developing breast cancer.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7337351-phenogen-sciences-introduces-brevagenplus-breast-cancer-risk-assessment-test/
Exact Sciences Corp. (NASDAQ: EXAS) announced today that the U.S. Food and Drug Administration (FDA) has approved Cologuard, the company’s noninvasive, stool DNA colorectal cancer screening test. Cologuard is the first noninvasive screening test for colorectal cancer that analyzes both stool DNA and blood biomarkers and has been proven to find 92 percent of cancers and 69 percent of the most advanced precancerous polyps in average risk patients. Cologuard, which is available through healthcare providers, offers people 50 and older at average risk for colorectal cancer an easy–to–use screening test they can do in the privacy of their own home.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7092251-fda-approve-s-exact-sciences-cologuard-screening-test-colorectal-cancer/
Bright Starts™ introduces a fun new metric, the Baby Laugh Index™, in tandem with the launch of three new toys designed to inspire laughter. The inspirations for the focus on laughter are the three new baby toys from the Bright Starts Having a Ball™ collection: 3-in-1 Step ’N; Ride Lion™, Hide ’N Spin Monkey™ and Jungle Fun Ball Climber™. Teaming up with Gina Mireault, Ph.D. professor of psychology and counseling behavior sciences at Johnson State College and researcher of humor and emotional development in children, Bright Starts seeks to emphasize the importance of laughter in infant development.
To view the multimedia assets associated with this release, please click: http://www.multivu.com/players/English/7251151-bright-starts-tm-introduces-fun-new-baby-laugh-index/
With or without a working knowledge of cannabis, most dispensary consumers have a speaking acquaintance with the compounds THC and CBD. But scientists are flirting with lesser known kinfolk in the cannabinoid family, compounds which are for the most part non-psychoactive but have intriguing potential health benefits. One such cannabinoid is Cannabinol, known in the industry as CBN.
CBN is a non-psychoactive cannabinoid that is a breakdown product of the cannabis superstar tetrahydrocannabinol (THC), the plant’s most abundant constituent best known for the plant’s psychoactive “high.” As the THC in cannabis buds ages, it transforms into cannabinol through a process known as oxidation.
To view the multimedia release go to:
https://www.multivu.com/players/English/8308957-gb-sciences-cannabis-brain-nurse-discusses-cbd-and-cbn/
USANA Health Sciences is pleased to announce an innovative technological advancement: its U.S. patent-pending USANA InCelligence Technology™. This exclusive cell-signaling technology—now found in various USANA® products—is designed to help your body’s cells renew and protect themselves in unique and powerful ways, representing a monumental leap forward in cellular nutrition and overall wellness.*
“USANA continues to build a reputation as an innovator in the science of cellular health and nutritional supplementation,” says USANA Founder Dr. Myron Wentz. “With USANA’s InCelligence Technology, we are ensuring that our company remains on the cutting-edge of nutritional supplementation.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7736551-usana-incelligence-technology/
